Molecular Imaging

For men with high clinical risk for prostate cancer (PCa) and a lack of significant findings on mpMRI, triage use of PSMA PET/CT resulted in a 49 percent reduction of biopsies and an 18 percent reduction in detection of clinically insignificant PCa, according to newly published research.

The Reporting Pro software reportedly offers an array of AI-enabled features that may help streamline radiology reports.

While researchers saw no significant difference in metastasis-free survival with the use of perioperative apalutamide in patients undergoing radical prostatectomy based on conventional imaging alone, the addition of PSMA PET imaging revealed a 20 percent higher likelihood of metastasis-free survival with adjunctive apalutamide.

The SubtleHD(PET) software reportedly facilitates enhanced image quality, provides improved SUVmax quantitative accuracy and compatibility with all FDA-approved radiotracers.

Catch up on the top radiology content of the past week.

While previous research has demonstrated the capability of the PET/CT agent (89Zr)girentuximab for detecting clear cell renal cell carcinoma (ccRCC), a new analysis reveals a 98 percent positive predictive value (PPV) for detecting non-ccRCC renal cancers.

Catch up on the top radiology content of the past week.

In a recent interview, Matthew Hulse, a certified nuclear medicine technologist, discussed the evolution of amyloid PET imaging in managing patients with Alzheimer’s disease, the impact on PET imaging volume and the emergence of quantification platforms for monitoring treatment efficacy.

Catch up on the most well-viewed video interviews from Diagnostic Imaging in April 2026.

Patients who had a total tumor volume (TTV) complete response (CR) on six-week SPECT/CT imaging had a 16 percent higher survival rate at two years in comparison to those who didn’t have TTV CR, according to new prospective research.

Catch up on the most-well viewed radiology content in April 2026.

Catch up on the first three episodes of our Molecular Imaging in Focus series featuring interviews with Gary Ulaner, MD, PhD, Louise Emmett, MBChB, FRACP, FAANMS, MD, and Jeremie Calais, MD, PhD.

Catch up on the top radiology content of the past week.

In a recent interview, Jeremie Calais, MD, PhD, shared his perspective on recent research that compared the risk stratification capabilities of nomogram models incorporating PSMA PET data to established clinical risk scoring models from the European Association of Urology and the National Comprehensive Cancer Network (NCCN).

In a recent interview, James Nagarajah, M.D., discussed new phase 2 research demonstrating significantly delayed disease progression in a cohort of patients with oligometastatic hormone-sensitive prostate cancer treated with 177-Lu-PSMA-617 and complete remission in nearly a quarter of these patients.

Catch up on the most-well viewed radiology content in March 2026.

Catch up on the top radiology content of the past week.

In a recent interview, Louise Emmett, MBChB, FRACP, FAANMS, MD, discussed recent findings from the Co-PSMA trial demonstrating enhanced detection of biochemical recurrence of prostate cancer with the PET agent 64Cu-SAR-bisPSMA.

Can the radioligand therapy 177Lu-PSMA-617 have an impact in older taxane-naïve men with mCRPC? Could we see the development of more combination therapies for patients with prostate cancer? Will emerging theranostics be effective in other targets beyond PSMA? Daniel George, M.D., addressed these topics and more in a recent interview.

Catch up on the top radiology content of the past week.

Emerging PSMA PET-based nomograms offered 12 percent and 14 percent higher AUCs than the European Association of Urology risk score for risk stratification of patients with biochemical recurrence of prostate cancer, according to an international, registry-based study involving over 11,000 patients.

Catch up on the top radiology content of the past week.

Catch up on a variety of new FDA clearances and approvals in radiology from the past week.

Catch up on the top radiology content of the past week.

Designed to enhance product stability at higher radioactive concentrations, the PSMA PET imaging agent Pylarify TruVu (piflufolastat F 18) may facilitate enhanced supply flexibility and access for men with suspected recurrence or metastasis of prostate cancer.